CTRI/2026/07/114068进行中（未招募）3 期
Clinical evaluation of safety and efficacy of three different dose regimens of erandamooladi niruha basti administered under kala basti schedule with reference to kostha madhyama and krura in patients of gridhrasi an open-labelled randomized comparative clinical trial - Nil
Dr uttam kumar sutradhar0 个研究点目标入组 90 人开始时间: 2026年8月15日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Diagnosed cases of gridhrasi with symptoms like ruka, toda, stambha, muhuspandana,tandra, gaurava, arochaka, Patients indicated for basti karma.
排除标准
- •History of spinal surgery and vertebral fracture.
- •evidence of systemic diseases like uncontrolled diabetes, hypertension, ischemic heart disease etc
- •established tumours/malignancy.
- •Patients having back pain due to non-spinal causes will excluded e.g., urinary tract infection, gastrointestinal disease and uterine diseases like pelvic inflammatory disease.
- •Anaemia haemoglobin less than 7.00 gm/dl
- •Subjects with symptoms of red flag signs.
- •Patients contraindicated for basti.
研究者
相似试验
招募中
1 期
Evaluation of the efficacy and safety of drug treatment in familial polycythemia associated with an EPO gene mutation: a multicentre, open-label, phase I trial2025-521906-16-00Centre Hospitalier Universitaire De Dijon4
进行中（未招募）
3 期
NN9838-7910: A research study to look at how two different doses of CagriSema and one dose of semaglutide help people living with obesity with or without type 2 diabetes lose weightNutritional, Metabolic, EndocrinePACTR202607641626021Novo Nordisk120
招募中
不适用
A clinical study to confirm the efficacy and safety of hard contact lenses for vision correction (SS-200)Corneal astigmatismjRCT203226029030
招募中
1 期
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.2025-522243-17-00Philogen S.p.A.96
招募中
2 期
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progressionGlioblastoma2022-501822-39-00Philogen S.p.A.113